Metabolic syndrome

Research Update

Topiramate Improves Weight in Schizophrenia in South Asians

Topics: Metabolic syndrome | Schizophrenia | Special populations | Topiramate | Weight gain

REVIEW OF: Chandradasa M et al, Asian J Psychiatr 2022;68:102963 STUDY TYPE: Randomized placebo-controlled trial People with schizophrenia have higher rates of cardiometabolic mortality. There is meta-analytic evidence that adjunctive topiramate reduces weight and improves psychiatric symptoms in schizophrenia. However, there are few studies of th

Read More
Clinical Update

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

Topics: Aripiprazole | Benzphetamine | Bupropion | Diabetes | Diethylpropion | Exercise | Insulin resistance | Liraglutide | Metabolic syndrome | Metformin | Naltrexone | olanzapine | Phendimetrazine | Phentermine | Samidorphan | Semaglutide | Side Effects | Topiramate | Waist circumference | Weight gain | Ziprasidone

Many psychiatric medications cause weight gain, including mood stabilizers, antidepressants, and especially antipsychotics. Most weight gain secondary to antipsychotic use occurs in the first 6 months of therapy, so it’s important to monitor weight closely and intervene early in a patient’s treatment. We counsel patients at every visit about healthy

Read More
Expert Q&A

Weight Gain and Metabolic Side Effects

Topics: Aripiprazole | Clozapine | Diabetes | Exercise | Insulin resistance | Liraglutide | Metabolic syndrome | Metformin | olanzapine | Quetiapine | Risperidione | Samidorphan | Side Effects | Topiramate | Waist circumference | Weight gain | Ziprasidone

CHPR: Dr. Marder, can you please tell us about your work? Dr. Marder: Sure. My work has focused on pharmacologic and nonpharmacologic approaches to improving the outcomes of serious mental illnesses, particularly schizophrenia. I’m very interested in ways to combine psychosocial interventions with pharmacological approaches and to reduce adverse side

Read More
Research Update

New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain

Topics: Metabolic syndrome | olanzapine | Opioid antagonist | Samidorphan | Schizophrenia | Weight gain

Review of: Correll CU et al, Am J Psychiatry 2020;177(12):1168–1178 To date, we have had no FDA-approved medications to mitigate antipsychotic-­associated weight gain (AIWG). This will soon change, thanks to recent research showing that samidorphan, an opioid receptor antagonist, appears to significantly lessen weight gain associated with the use

Read More

Antipsychotic Maintenance: How Long is Enough?

Topics: Antidepressant Augmentation | Antidepressants | Antipsychotics | Bipolar Disorder | Deprescribing | Depression | Depressive Disorder | Mania | Metabolic syndrome | Mood Stabilizers | olanzapine | Psychopharmacology | Psychopharmacology Tips | Risperidone | Side Effects | Tardive dyskinesia

Your 58-year-old patient started risperidone to augment lithium 2 years ago. It got her out of a severe mania, and she has stayed well since then. Now she’s worried about long-term risks and wondering if it’s time to come off. Augmentation with an atypical antipsychotic may offer rapid relief from mania and depression, but antipsychotics’ potenti

Read More
In Brief

Lybalvi: The Diet Olanzapine

Topics: Antipsychotics | Metabolic syndrome | Metformin | News of Note | Novel drug | Obesity | olanzapine | Side Effects | Waist circumference | Weight gain | Weight Loss Medications

Lybalvi is a new combo pill that aims to overcome the dreaded metabolic effects of olanzapine by pairing it with the opioid antagonist samidorphan. Patients still gain weight on Lybalvi, though not as much as they do on olanzapine. In the three controlled trials that compared the two drugs, the weight gain on Lybalvi was 5 lb less at six months, 3 lb le

Read More
Research Update

Omega-3s and Metabolic Risks in Schizophrenia

Topics: Complementary treatments | Complimentary Medicine | Diabetes | Medical Comorbidities | Metabolic syndrome | Metformin | Natural Medications | natural treatments | Negative Symptoms | Omega-3 | Research Update

REVIEW OF: Pawełczyk T et al, Schizophr Res 2021;230:61–68 TYPE OF STUDY: Randomized, double-blind, placebo-controlled trial Patients with schizophrenia are at greater risk for metabolic syndrome, whether from lifestyle, antipsychotic side effects, or the illness itself. Omega-3 fatty acids have metabolic benefits in the general population, and lev

Read More